Medical AI Compliance in San Diego (2026): Life Sciences & MedTech Checklist
San Diego's Torrey Pines Mesa is one of the densest concentrations of life sciences and biotech companies in the world — and four California AI laws that took effect January 1, 2026 apply directly to AI-powered products in this ecosystem. AB 489, AB 3030, AB 2013, and SB 1120 create patient disclosure, clinical communication oversight, training data transparency, and claim denial restrictions that apply on top of FDA clearance.
San Diego's Dual Regulatory Environment
San Diego County is home to more than 1,600 life sciences, biotech, and MedTech companies — the third-largest concentration in the United States. The Torrey Pines Mesa corridor, Sorrento Valley, and Kearny Mesa host companies spanning genomics, digital therapeutics, medical imaging AI, clinical trial platforms, and patient-facing health AI applications.
San Diego companies typically have well-developed FDA compliance programs — 510(k) clearance, De Novo authorization, IDE protocols, and 21 CFR Part 11 documentation are routine. What many San Diego life sciences companies lack is an equivalent framework for California's 2026 AI laws, which target a different compliance dimension: how AI communicates with patients, not how it was validated as a device.
The result is a dual regulatory burden that creates gaps where FDA clearance provides false confidence. A cleared AI system can simultaneously violate AB 3030 because it sends AI-generated clinical messages to patients without human review, and violate AB 2013 because it never published a training data disclosure.
The Four Laws: Side-by-Side Reference
| Law | What It Requires | Who It Hits | Penalty |
|---|---|---|---|
| AB 489 | AI must disclose it is not human at start of every patient interaction | All patient-facing AI | Medical Board disciplinary action |
| AB 3030 | GenAI clinical communications need human review or specific disclaimer | Healthcare providers using GenAI | $2,500/violation + full liability |
| AB 2013 | Public training data disclosure required on your domain | GenAI developers and deployers | AG enforcement; blocks procurement |
| SB 1120 | AI cannot autonomously deny health insurance claims | Utilization management AI tools | Regulatory action; contract liability |
AB 489 — AI Identity Disclosure
For San Diego life sciences and MedTech companies with patient-facing AI systems, AB 489 requires clear disclosure at the start of every patient interaction that the system is not a licensed healthcare professional. High-risk product categories in San Diego's portfolio include:
- Digital therapeutic applications that provide AI-guided health interventions
- Genomics patient portals with AI-generated variant interpretation explanations
- Remote patient monitoring platforms with AI-driven alerts and follow-up messaging
- Clinical trial patient communication tools using AI to answer protocol questions
Common San Diego violation pattern
Genomics and precision medicine platforms that send AI-generated variant interpretation reports or risk explanations directly to patients — without disclosing the AI's role — violate AB 489 if the patient could reasonably interpret the report as coming from a licensed physician or genetic counselor. The disclosure must appear before any clinical content is exchanged.
AB 3030 — Generative AI in Clinical Communications
San Diego life sciences companies most commonly encounter AB 3030 when their AI systems generate patient-directed clinical content as a byproduct of clinical workflows:
- AI-generated variant interpretation letters sent to patients based on genomic test results
- Automated discharge instruction summaries drafted by LLMs from procedure notes or EHR data
- Digital therapeutic progress reports generated by AI and sent to patients at defined intervals
- Clinical trial update communications tailored by AI to individual participant status
The compliance choice: (1) a licensed clinician reviews each AI output before it reaches the patient — which requires workflow infrastructure but eliminates disclaimer obligations — or (2) the communication carries a specific disclaimer that it was produced by AI, was not reviewed by a human provider, and includes instructions for reaching one.
AB 2013 — Training Data Transparency for Life Sciences AI
AB 2013 is the law most often missed by San Diego life sciences companies because it targets the model development layer — invisible to patients but critical for procurement. AB 2013 applies when a company:
- Trains a foundation model on published medical literature, clinical datasets, or proprietary genomic data
- Fine-tunes an existing LLM on trial data, pathology reports, or clinical notes
- Develops AI that generates text, structured reports, or interpretations for any user population
- Uses RLHF or similar training techniques with physician-rated clinical outputs
The required disclosure must cover data categories, date ranges, PII/HIPAA data handling, and a modification history for any substantial model retraining. It must be hosted at a publicly accessible URL on your company's own domain — not embedded in a research paper citation or behind a login.
Free tool: Generate your AB 2013 disclosure
Our free AB 2013 Training Data Transparency Generator creates a compliant, ready-to-publish disclosure page. Enter your data categories and receive publication-ready HTML in minutes. No signup required.
Open Transparency Generator →SB 1120 — Utilization Management
San Diego biotech and health IT companies building tools for health plans, prior authorization platforms, or clinical utilization review must comply with SB 1120. A licensed, qualified clinician must make the final determination on coverage denials — AI cannot be the decision-maker. This applies to both direct-to-payer products and provider-facing tools whose outputs are used in downstream payer decisions.
What San Diego Health Systems Require at Vendor Procurement
San Diego health systems — including UC San Diego Health, Scripps Health, Sharp Healthcare, Rady Children's Hospital, and Palomar Health — are updating AI vendor risk questionnaires. Typical documentation requirements include:
- Evidence of AB 489 disclosure in the patient-facing product (screenshots or live demonstration)
- Written AB 3030 human-review workflow policy or deployed disclaimer language
- The public URL for the company's AB 2013 training data disclosure page
- Attestation that AI does not autonomously issue clinical determinations without licensed human oversight
- Audit log samples demonstrating disclosure timestamps and, where applicable, clinician approval records
The 2026 San Diego MedTech AI Compliance Checklist
AB 489 — Patient-Facing AI Identity
- ☐ Every patient-facing AI interaction starts with a clear, prominent AI identity disclosure
- ☐ Disclosure appears before any clinical content is exchanged
- ☐ Disclosure reappears at the start of every new session
- ☐ AI avatars carry no clinical camouflage (no white coats, stethoscopes, clinical titles)
- ☐ Disclosure explicitly states the system is not a licensed healthcare professional
- ☐ Every AI interaction provides a pathway to reach a human staff member
AB 3030 — Generative AI Patient Communications
- ☐ All AI-generated patient communications are inventoried and classified
- ☐ For each type: human review workflow is documented OR disclaimer is deployed
- ☐ Human review policy names specific licensed reviewers with clinical credentials
- ☐ AI-generated communications sent without review carry the full AB 3030 disclaimer
- ☐ Disclaimer includes instructions for the patient to reach a human provider
- ☐ Audit logs capture AI outputs, reviewer identities, approval decisions, and timestamps
AB 2013 — Training Data Transparency
- ☐ Training data disclosure is published at a public URL on your domain
- ☐ Disclosure names all data categories — licensed, scraped, synthetic, proprietary genomic
- ☐ HIPAA-regulated data use is documented with de-identification method specified
- ☐ Modification history section covers all substantial retraining events
- ☐ Disclosure URL is included in all hospital and payer vendor questionnaire responses
- ☐ A process exists to update the disclosure when the model is substantially retrained
SB 1120 — Utilization Management (if applicable)
- ☐ AI does not autonomously issue coverage denials or final clinical determinations
- ☐ Utilization management vendor contracts require SB 1120-compliant human review
- ☐ Licensed clinician review is documented for every denial where AI was involved
30-Day Compliance Action Plan
Week 1 — Audit and map. Inventory every AI touchpoint that communicates with patients or generates clinical content. Identify which California law applies to each. Note every gap where disclosures are missing or AI outputs reach patients without human review.
Week 2 — Fix AB 489 disclosures. Implement clear AI identity disclosures at every patient-facing entry point. Check all AI avatar designs for clinical camouflage. Use our free Disclosure Generator to create law-compliant disclosure text.
Week 3 — Implement AB 3030 workflows. Assign licensed reviewers to AI-generated clinical communications or deploy AB 3030 disclaimers on automated outputs. Document the chosen approach and build audit logging.
Week 4 — Publish AB 2013 disclosure and prepare procurement documentation. Generate and publish your training data transparency page using our free AB 2013 Transparency Generator. Build your hospital vendor documentation package for Scripps, UCSD Health, Sharp, and Rady procurement reviews.
Penalties and Enforcement
All four laws took effect January 1, 2026. AB 3030 penalties reach $2,500 per violation per patient interaction missing required disclosures. The California Attorney General has civil enforcement authority over AB 2013 failures, with potential UCL §17200 claims for deceptive business practices. San Diego life sciences companies with hospital or payer contracts face the additional risk that compliance gaps surface during security reviews and stall or disqualify vendor relationships.